Midlantic Urology

Bala-Cynwyd, Pennsylvania 19004

14 studies enrolling now · 46 studies all time

What they study most

Abiraterone Acetate, Advanced Prostate Adenocarcinoma, Androgens, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Benign Prostatic Hyperplasia, Biochemically Recurrent Prostate Carcinoma, Bladder Cancer, Bladder Pain Syndrome, Cancer of the Prostate, Castration-Resistant Prostatic Cancer, Castration-resistant Prostate Cancer

Studies at this site

• A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer — Recruiting now
• Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer — Recruiting now
• Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer — Recruiting now
• A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) — Recruiting now
• A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer — Recruiting now
• A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer — Recruiting now
• This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. — Recruiting now
• Trial of Ureteroscopy vs Steerable Continuous Flow Aspiration Technology — Recruiting now
• Sacral Neuromodulation for Male Overactive Bladder (MOAB) — Recruiting now
• Study of ORIC-944 in Patients With Metastatic Prostate Cancer — Recruiting now
• A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer — Recruiting now
• An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) — Recruiting now
• A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer — Recruiting now
• Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T — Recruiting now
• A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy — Running, not enrolling
• A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer — Running, not enrolling
• A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder — Running, not enrolling
• SpaceIT Hydrogel System for Perirectal Spacing — Running, not enrolling
• A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer — Running, not enrolling
• A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) — Running, not enrolling
• A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT — Running, not enrolling
• A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder — Completed
• Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer — Running, not enrolling
• Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate — Completed
• A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer — Running, not enrolling
• A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases — Completed
• An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG — Available (expanded access)
• A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer — Running, not enrolling
• Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome — Completed
• INTIBIA Pivotal Study — Running, not enrolling
• A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) — Completed
• A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors — Completed
• 177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer — Running, not enrolling
• Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer — Running, not enrolling
• Acoustic Enhancer Research on Laser Lithotripsy (AEROLITH) — Completed
• A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome — Stopped early
• HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Stopped early
• Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management — Status unconfirmed
• Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System — Stopped early
• To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer — Stopped early
• A Study to Evaluate Androderm®'s Effect on Blood Pressure in Adult Hypogonodal Male Participants — Completed
• PROCLAIM: Germline Genetic Testing for Prostate Cancer Patients — Completed
• PSD502 in Subjects With Premature Ejaculation — Completed
• A Registry for Hereditary Cancer Risk Assessment and Genetic Testing — Completed
• Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC — Stopped early
• Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer — Completed